Post-TRT HPG Axis Restart: Suppression Kinetics, LH Receptor Recovery, and Evidence

Exogenous testosterone creates supra-physiologic androgen concentrations at the hypothalamus that suppress GnRH pulsatility through two mechanisms: direct androgen receptor (AR) activation on hypothalamic GnRH neurons, and aromatase-mediated conversion of excess testosterone to estradiol (E2), which activates estrogen receptor alpha (ERα) on GnRH neurons — the dominant negative feedback signal in males. Together, these suppress GnRH pulse frequency within days of TRT initiation, reducing LH and FSH to below-detection levels within 2–4 weeks.

At the pituitary level, chronic absence of GnRH pulsatility leads to GnRH receptor downregulation in gonadotroph cells and reduced LH/FSH secretory granule content — a use-dependent atrophy of the gonadotroph population. This pituitary-level atrophy is reversible but requires weeks to months: GnRH receptor re-expression takes 2–4 weeks after GnRH pulsatility resumes, and gonadotroph secretory capacity recovery tracks receptor recovery. Critically, recovery requires normal-range GnRH pulsatility to resume — if hypothalamic GnRH recovery is slow (as it is after extended TRT), pituitary recovery follows rather than leading. Post-TRT interventions that amplify GnRH pulsatility (or LH signaling) therefore target the rate-limiting step in the restart cascade.

Leydig cells undergo two distinct changes during TRT-induced LH suppression. First, LH receptor expression is downregulated: in the absence of LH stimulation, Leydig cells reduce LH receptor synthesis and increase receptor internalization (LH receptor is a G-protein coupled receptor subject to agonist-induced internalization — but also to atrophic downregulation in chronic absence of agonist). This creates a paradox at TRT discontinuation: when LH begins recovering, the Leydig cells initially have reduced receptor density to respond to the returning signal, creating a lag between LH recovery and testosterone recovery.

Second, testicular volume — a direct proxy for Leydig cell number and spermatogenic tubule diameter — decreases during TRT through both Leydig cell atrophy and Sertoli cell/spermatocyte loss from FSH suppression. The structural atrophy component means testosterone recovery after TRT is not purely a signaling problem — some degree of Leydig cell repopulation from adrenal precursor cells is required, a process taking 3–6 months in a normally recovering axis. Duration of TRT is a primary predictor: men with >24 months of TRT show significantly longer recovery timelines (median 9–12 months in observational series) compared to <12 months (median 4–6 months). These timelines inform minimum supplement protocol durations for realistic HPG axis reactivation goals.

Eurycomanone from Eurycoma longifolia is the most evidence-supported botanical compound for HPG axis reactivation in the post-TRT context. Its mechanism — stimulation of LH release from pituitary gonadotrophs and competition for SHBG binding sites — addresses both the central signaling deficit (LH amplitude) and the peripheral bioavailability constraint (SHBG competing with endogenously produced testosterone for receptor binding). In the post-TRT axis, where both LH pulse amplitude and Leydig cell receptor sensitivity are suboptimal, a compound that amplifies the LH signal is mechanistically well-matched to the deficit.

The 2022 meta-analysis (PMID 36013514) reporting SMD = 1.35 in hypogonadal men is the most directly applicable evidence base for post-TRT use — the hypogonadal state of post-TRT recovery is mechanistically analogous to functional hypogonadism in the meta-analysis populations (low-to-normal LH, low testosterone, intact but underactivated Leydig cells). In post-TRT recovery, eurycomanone's LH-amplifying effect supports the recovering pituitary in stimulating Leydig cells that are gradually recovering receptor density. Pharmacokinetic modeling suggests 200 mg/day LJ100 extract maintains sufficient eurycomanone plasma concentrations to achieve the LH-amplifying effect continuously.

Fadogia agrestis is a West African shrub that has achieved widespread popularity in social media "post-cycle therapy" communities based on animal data showing LH-like activity and testosterone increases in rodent models. It is essential that any serious technical discussion of fadogia address the toxicological evidence directly: multiple rodent studies demonstrate dose-dependent testicular toxicity, with histological findings including seminiferous tubule disruption, Leydig cell vacuolization, and spermatogenic arrest at doses that scale in approximate proportion to popular human supplement doses.

A critical published study in Scientia Pharmaceutica found that fadogia agrestis extract in male rats produced significant testicular damage at the rodent equivalent of moderate human doses, with effects on sperm quality and Leydig cell morphology. No human RCT data exist for fadogia agrestis — zero. The compound has no peer-reviewed safety or efficacy data in human subjects. The disconnect between social media promotion and actual evidence is at its most dangerous with fadogia in the post-TRT context, where men with already-compromised Leydig cell function are supplementing with a compound whose primary documented biological effect on testes — in the only available published models — is toxicity. Helian does not formulate with fadogia agrestis and this position is non-negotiable based on the available evidence.